Last reviewed · How we verify
Diclofenac 1%
Diclofenac 1% is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Daré Bioscience, Inc.. It is currently FDA-approved for Topical treatment of localized pain and inflammation associated with osteoarthritis, musculoskeletal injuries, and other localized inflammatory conditions. Also known as: Diclofenac Heumann gel.
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Topical treatment of localized pain and inflammation associated with osteoarthritis, musculoskeletal injuries, and other localized inflammatory conditions.
At a glance
| Generic name | Diclofenac 1% |
|---|---|
| Also known as | Diclofenac Heumann gel |
| Sponsor | Daré Bioscience, Inc. |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Diclofenac blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels at the site of application (topical 1% formulation), it provides localized anti-inflammatory and analgesic effects with potentially lower systemic exposure compared to oral formulations.
Approved indications
- Topical treatment of localized pain and inflammation associated with osteoarthritis, musculoskeletal injuries, and other localized inflammatory conditions
Common side effects
- Local skin irritation or rash
- Pruritus
- Erythema
- Systemic NSAID-related gastrointestinal effects (with significant absorption)
Key clinical trials
- Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis (NA)
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy (PHASE2)
- Clinical Application of Dynamic Multimodal Analgesia Regimen After Perianal Abscess Surgery (NA)
- Topical Chemoprevention of Skin Cancer Biomarkers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diclofenac 1% CI brief — competitive landscape report
- Diclofenac 1% updates RSS · CI watch RSS
- Daré Bioscience, Inc. portfolio CI
Frequently asked questions about Diclofenac 1%
What is Diclofenac 1%?
How does Diclofenac 1% work?
What is Diclofenac 1% used for?
Who makes Diclofenac 1%?
Is Diclofenac 1% also known as anything else?
What drug class is Diclofenac 1% in?
What development phase is Diclofenac 1% in?
What are the side effects of Diclofenac 1%?
What does Diclofenac 1% target?
Related
- Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
- Target: All drugs targeting COX-1 and COX-2
- Manufacturer: Daré Bioscience, Inc. — full pipeline
- Therapeutic area: All drugs in Pain Management / Rheumatology
- Indication: Drugs for Topical treatment of localized pain and inflammation associated with osteoarthritis, musculoskeletal injuries, and other localized inflammatory conditions
- Also known as: Diclofenac Heumann gel
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing